Phase II study of combination therapy with S-1 and irinotecan in EGFR-mutated non-small cell lung cancer (NSCLC) resistant to both platinum-based chemotherapy and EGFR-TKI: NJLCG0804
Phase II study of combination therapy with S-1 and irinotecan in EGFR-mutated non-small cell lung cancer (NSCLC) resistant to both platinum-based chemotherapy and EGFR-TKI: NJLCG0804
复制标题
S-1 和伊立替康联合治疗对铂类化疗和 EGFR-TKI 耐药的 EGFR 突变非小细胞肺癌 (NSCLC) 的 II 期研究：NJLCG0804
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Nukiwa T
中科院分区：
文献类型：
--
作者：
Maemondo M;Sugawara S;Harada T;Fukumoto S;Inoue A;Ishimoto O;Matsubara N;Harada M;Kobayashi K;Nukiwa T
